Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells

Yasuo Yoneyama, Yasuji Ueda, Yasunori Akutsu, Akinao Matsunaga, Hideaki Shimada, Tomonori Kato, Megumi Kubota-Akizawa, Shinji Okano, Satoko Shibata, Katsuo Sueishi, Mamoru Hasegawa, Takenori Ochiai, Yoshikazu Yonemitsu

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Dendritic cell (DC)-based immunotherapy has been clinically evaluated, however, still requires modification to improve its outcomes. We previously demonstrated that DCs activated by replication competent recombinant Sendai virus (SeV) showed dramatic efficacy over that seen in use of current DC vaccine for immunotherapy against malignancies; however, application of replication-deficient vector is more relevant in clinical setting. We here show that F-gene-deleted non-transmissible Sendai virus (SeV/dF)-activated DCs (DCs/SeV/dF) has strong antitumor effects against murine SCCVII tumor, that was well-known as a less immunogenic cell line. SeV/dF shows high transfection efficiency to DCs and leads them to upregulate costimulatory molecules. Intratumoral injection of DCs/SeV/dF resulted in a marked and representative inhibition of the tumor, even when the tumors were well-vascularized. This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/dF-based cancer immunotherapy may, therefore, warrant further investigation.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalBiochemical and Biophysical Research Communications
Issue number1
Publication statusPublished - Mar 30 2007

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells'. Together they form a unique fingerprint.

Cite this